Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 08 Aug 2024 Status changed from not yet recruiting to recruiting.
- 13 May 2024 Planned initiation date changed from 15 Apr 2024 to 20 Jul 2024.
- 01 Mar 2024 Planned initiation date changed from 15 Jan 2024 to 15 Apr 2024.